John Wagner
Affiliations: | Dana-Farber Cancer Institute, Boston, MA, United States |
Google:
"John Wagner"Mean distance: 15.45 (cluster 11)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Caro L, de Hoon J, Depré M, et al. (2017) Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men. Clinical and Translational Science |
| Hulskotte E, Gupta S, Xuan F, et al. (2012) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (Baltimore, Md.). 56: 1622-30 |
| Forman M, Tseng J, Palcza J, et al. (2012) The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF A Peptides in Healthy Subjects: Results from a Rising Single Dose Study (PL02.004) Neurology. 78 |
| Min K, Forman M, Dockendorf M, et al. (2012) A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK-8931 in Japanese subjects Alzheimers & Dementia. 8: 186 |
| Tseng J, Dockendorf M, Krishna G, et al. (2012) Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single- and Multiple-Dose administration Alzheimers & Dementia. 8 |
| Luo W, Crumley T, Ebel D, et al. (2010) Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers The Journal of Clinical Pharmacology. 50: 1273-1279 |
| Radziszewski W, Lai E, Lazarus Shipitofsky N, et al. (2010) A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. American Journal of Therapeutics. 17: 8-16 |
| Stoch SA, Zajic S, Stone J, et al. (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clinical Pharmacology and Therapeutics. 86: 175-82 |
| Wenning LA, Petry AS, Kost JT, et al. (2009) Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clinical Pharmacology and Therapeutics. 85: 623-7 |
| Brainard D, Wright D, Sneddon K, et al. (2009) 937 SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE DOSES OF MK-3281 IN HEALTHY SUBJECTS Journal of Hepatology. 50: S341 |